間質性膀胱炎治療薬の世界市場:インサイト・疫学・市場予測

◆英語タイトル:Interstitial Cystitis Market Insight, Epidemiology and Market Forecast -2030
◆商品コード:DELV20JU068
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年5月
◆ページ数:200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(68名様閲覧)USD6,950 ⇒換算¥729,750見積依頼/購入/質問フォーム
Three UserUSD10,425 ⇒換算¥1,094,625見積依頼/購入/質問フォーム
Site LicenseUSD13,900 ⇒換算¥1,459,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s “Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Interstitial Cystitis market report provides current treatment practices, emerging drugs, Interstitial Cystitis market share of the individual therapies, current and forecasted Interstitial Cystitis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Interstitial Cystitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Interstitial Cystitis Disease Understanding and Treatment Algorithm
Interstitial Cystitis (IC), also called as Painful Bladder Syndrome, is a chronic condition causing bladder pressure, bladder pain and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. Bladder is a hollow, muscular organ that stores urine. The bladder expands until it is full and then gives signals to the brain that it is time to urinate, communicating through the pelvic nerves. This creates the urge to urinate for most people. With IC, these signals get mixed up and then patients feel the need to urinate more often and with smaller volumes of urine than most people. The IC disease most often affects women and can have a long-lasting impact on the quality of life. Although there is no cure, medications and other therapies may offer some relief.

There are two types of IC such as Non-Ulcerative, which is found in 90% of the population suffering from Interstitial Cystitis. It is characterized by pinpoint hemorrhages called as glomerulations. Another types is Ulcerative, which comprises of about 5–10% of the patient population. . It is mainly characterized by Hunner’s ulcers and the patches that bleed on bladder walls. Hunner’s ulcers, also called “Hunner’s lesions” or “Hunner’s patches,” are a subtype of Interstitial Cystitis (also called IC) and are not ulcers in the usual sense. They are distinctive areas of inflammation on the bladder wall that characterize the “classic” form of IC. Hunner’s ulcers are the one diagnostic feature that clinches the IC diagnosis, but this “classic” form of IC affects only about 5 to 10 percent of patients. Often, patients with this form of IC have more severe symptoms than patients with non-ulcerative IC.

The DelveInsight Interstitial Cystitis market report gives the thorough understanding of the IC by including details such as disease introduction, signs and symptoms, risk factors, causes, pathophysiology, biomarkers and diagnosis. It also provides treatment algorithms and treatment guidelines for AKI in the US, Europe, and Japan.

Diagnosis

A thorough general medical history is of paramount importance to identify typical diagnostic symptoms of IC/BPS and other potential mimicking causative conditions. Unfortunately, delay of diagnosis is common, with an average time of 3–7 years from the time of presentation to the general practitioner to diagnosis by a specialist.

Despite the absence of urinary infection (UTI) being a prerequisite at the time of diagnosis, up to 50% of patients will have a previous history of UTI. It is important to elicit a comprehensive medical history, including past pelvic surgery or radiation, medications that can cause cystitis (nonsteroidal anti-inflammatory drugs, cyclophosphamide, and ketamine), fibromyalgia, depression, sexual dysfunction, autoimmune diseases, allergies, and other gynecological conditions (vulvodynia, endometriosis, dyspareunia). Not only is the past medical history important for diagnosis, but also because many of these conditions may co-exist, further stressing the importance of multidisciplinary management.

The most commonly used methods to diagnose IC include physical examination, ultrasound/pelvic imaging, laboratory tests such as urinalysis, culture, cytology, potassium sensitivity test, etc.

Treatment

Since the etiology and pathogenesis of IC are not well understood and there is no curative treatment, the goal of management is to provide relief of symptoms to improve quality of life of the patients. However, still bladder pain syndrome can be treated using a step wise approach depending upon the identified risk of adverse effects and invasiveness of the treatment options. The therapeutic options used to treat IC include over the counter medicines (Aspirin, Acetaminophen, NSAIDs, etc.), non-narcotic pain medicines (Pyridium, Topical Medicines, Lidocaine Patch, etc.), narcotic pain medicines (Codeine, Oxycodone, Tapentadol, etc.)

Other interventions include use of physical therapy, antidepressants, selective serotonin reuptake inhibitors (SSRIS), serotonin and norepinephrine reuptake inhibitors (SNRIS), Bladder Instillations, Immunosuppressants, etc.

Till date there are only two approved therapies to treat IC such as oral Elmiron (Pentosan polysulfate sodium) and intravesical Dimethyl Sulfoxide (DMSO).

Interstitial Cystitis Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Interstitial Cystitis, Gender-specific Prevalent Population of Interstitial Cystitis, Total Diagnosed Prevalent Population of Interstitial Cystitis, Severity-based Diagnosed Prevalent Population of Interstitial Cystitis, Type-specific Diagnosed Prevalent Population of Interstitial Cystitis, Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpse of the Interstitial Cystitis (IC) epidemiology in the 7MM.

The total diagnosed prevalent population of Interstitial Cystitis in the 7 major markets was found to be 2,264,118 in 2017. In case of Interstitial Cystitis patients in the United States, the diagnosed prevalent cases was found to be 1,459,502 in 2017.
The prevalent population of Interstitial Cystitis in the United States was found to be 5,838,009 in 2017, which is expected to increase by 2030.
DelveInsight has analyzed severity-based data for Interstitial Cystitis. Interstitial Cystitis can be divided as three types based on this data, namely, mild, moderate and severe type. It was found that in the United States the number of cases of mild, moderate and severe were 525,421, 729,751 and 204,330 respectively in 2017.
In Japan, the diagnosed prevalence of Interstitial Cystitis was found to be 151,513 in 2017, which will increase in the forecast period 2020–2030.

Country Wise- Interstitial Cystitis Epidemiology

The epidemiology segment also provides the Interstitial Cystitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Interstitial Cystitis Drug Chapters
The drug chapter segment of the Interstitial Cystitis (IC) report encloses the detailed analysis of Interstitial Cystitis (IC) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Interstitial Cystitis (IC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Interstitial Cystitis Marketed Drugs

Elmiron: Janssen Pharmaceutical

Elmiron (Pentose polysulfate sodium) is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects. It is formulated for oral use. Elmiron is indicated for the relief of bladder pain or discomfort associated with Interstitial Cystitis. It is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. It is a white odorless powder, slightly hygroscopic and soluble in water to 50% at pH. Elmiron is supplied in white opaque hard gelatin capsules containing 100 mg pentosan polysulfate sodium, microcrystalline cellulose, and magnesium stearate.

Product detail in the report…

RIMSO-50: Mylan Pharmaceutical

Rimso-50 also known as Dimethyl Sulfoxide (DMSO) is first and only FDA approved bladder instillation that is specifically being developed for Interstitial Cystitis. RIMSO-50 is a 50% w/w aqueous solution for intravesical instillation. Dimethyl sulfoxide is a clear, colorless and essentially odorless liquid which is miscible with water and most organic solvents. RIMSO-50 acts as anti-inflammatory (it reduces bladder irritation and pain), antispasmodic (helps in relaxing bladder and pelvic muscles) and relives pain by depleting the level of P substance in bladder nerves. It increases bladder capacity by breaking the scar tissues and preventing the formation of collagen that creates scar tissue. Dimethyl Sulfoxide is clear and colorless

However, there are several other intravesical instillations approved by the regulatory authorities that are used to provide relief to the patients with IC.

Product detail in the report…

Interstitial Cystitis Emerging Drugs

KRP-116D: Kyorin Pharmaceutical

KRP-116D is a 50% w/w DMSO solution, which is administered intravesically and allowed to remain in the bladder for 15 min. Kyorin Pharmaceutical has planned the development of 50% DMSO (KRP-116D) for the treatment of IC/BPS based on a request from the Committee on Unapproved Drugs and Drugs of Off-label Use urgently required for healthcare organized by the Ministry of Health, Labour and Welfare, Japan. Evidences suggest that the patient notes a garlic-like taste within a few minutes after intravesical instillation of 50% DMSO, which persists for several hours, and that an odor on the breath and skin may remain for 72 h; this suggests that DMSO is absorbed from the bladder into the body. The drug has already completed phase III clinical developmental trial in Japan for interstitial cystitis, and the company is preparing for application for the approval of the drug.

Product detail in the report…

Certolizumab pegol (Cimzia): UCB Pharma

Certolizumab pegol (Cimzia) is the only Fc-free, PEGylated anti-TNF (Tumor Necrosis Factor). It has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Certolizumab pegol binds to human TNFα with a KD of 90 pM; TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes. The drug selectively neutralizes TNFα (IC90 of 4 ng/mL for inhibition of human TNFα in the in vitro L929 murine fibrosarcoma cytotoxicity assay) but does not neutralize lymphotoxin α (TNFβ). It is also shown to neutralize membrane-associated and soluble human TNFα in a dose-dependent manner. UCB Pharma has completed its investigation of Cimzia in phase III clinical developmental trial for the treatment of patients with IC in July 2017 itself. The complete results of this trial were published in 2018; however, the company has not published any recent updates since then. Additionally, the drug is also indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA), plaque psoriasis, Crohn’s disease (CD), adults with active psoriatic arthritis (PsA), and adults with active ankylosing spondylitis (AS).

Product detail in the report…

LP-08: Lipella Pharmaceuticals

LP-08, investigated by Lipella Pharmaceuticals, is a novel intravesical treatment for IC, a poorly understood chronic disorder of unknown etiology consisting of irritative bladder symptoms and pelvic pain that dramatically affects the quality of life. LP-08 is a patent-protected investigational drug for IC comprised of pure liposomes. The purified phospholipid component of LP-08 is known to be safe as a food source when eaten or delivered as a component of intravenous nutrition. There is no expectation that a novel route of bladder administration will present any safety issues. The company has completed its investigation of the safety and efficacy of LP-08 in phase II clinical developmental trial in June 2018 for IC.

Product detail in the report…

GRT6010: Grünenthal

Grünenthal is developing GRT6010 for the treatment of Interstitial Cystitis. It is a novel analgesic and nociceptin opioid receptor (NOP) agonist. The company has completed the phase II clinical trial for the treatment of IC in Germany, and the results were published in December 2018.

Product detail in the report…

ASP6294: Astellas Pharma

ASP6294, being developed by Astellas Pharma, is a Nerve Growth Factor (NGF) neutralization antibody. NGF is responsible for the growth and maintenance of sensory neurons and appears to play a role in neuroimmune interactions, in tissue inflammation, and neuroplasticity for neuronal events leading to OAB and bladder pain/interstitial cystitis. ASP6294 inhibits the NGF, thereby blocking its role in bladder pain. The product has completed phase II clinical trial for the treatment of BPS/IC. The drug has completed phase II trial in March 2019.

Product detail in the report…

SI-722: Seikagaku Corporation

SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku’s proprietary glycosaminoglycan (GAG) modification technology and drug delivery systems (DDS). Intravesically instilled SI-722 provides sustained release of the steroid having anti-inflammatory activity resulting in a demonstration of long-lasting improvement in the conditions of frequent urination and bladder pain. The company follows a drug discovery approach of increasing the bioactivity of GAG, mainly through GAG modification and processing, and is currently applying GAG to DDS. It is designed for sustained release by bonding steroids to chondroitin sulfate; this leads to anti-inflammatory effects of steroids under sustained release, which should provide sustainable relief of frequent urination and bladder pain, thereby, improving patient’s quality of life. SI-722 has completed a phase I clinical study in the US. As per clinicaltrials.gov, the drug is in phase I/II developmental clinical trial for IC/BPS. This clinical study will evaluate the drug for safety, tolerability, and pharmacokinetics, and will conduct an exploratory evaluation of its effectiveness.

Product detail in the report…

Interstitial Cystitis Market

Interstitial Cystitis Market Outlook
According to the Interstitial Cystitis Association (ICA), interstitial cystitis or IC, is a bladder condition that usually consists of multiple symptoms. Most IC patients have recurring pelvic pain, pressure, or discomfort in the bladder and pelvic region, and urinary frequency and urgency (feeling a strong need to go). IC may also be referred to as painful bladder syndrome (PBS), bladder pain syndrome (BPS), and chronic pelvic pain. Approximately, 3–8 million women in the United States may have IC, which constitutes about 3–6% of all women in the US. On the other hand, 1–4 million men have IC as well. However, this number is likely lower than the actual rate because IC in men may often be mistaken for another disorder, such as chronic prostatitis/chronic pelvic pain syndrome.

Oral pentosan polysulfate sodium (PPS) and intravesical dimethyl sulfoxide (DMSO) are the only The US Food and Drug Administration (FDA) approved treatments for the relief of IC symptoms. Fortunately, a variety of other therapies are often used alone or in combination for the treatment of IC. Among these orally administered therapies, only Elmiron (Pentosan polysulfate sodium; Janssen Pharmaceuticals) is approved by the US Food and Drug Administration (FDA) for the treatment of IC.

The US FDA approved it in September 1996. Pentosan Polysulfate is a semisynthetic heparin-like glycosaminoglycan. On the other hand, intravesical instillations with anesthetic solutions are used to control bladder pain, and heparin agents as they are thought to repair the damaged urothelium. The American Urological Association’s practice guideline for IC indicates bladder installations as a second-line treatment option when diet modification, stress management, and over-the-counter products are not enough. Bladder instillations or bladder cocktails are mixtures of medicines when introduced directly into the bladder.

Types of instillations include Alkalinized Lidocaine and Heparin, DMSO, Sodium Hyaluronate, and BCG. Among these, Dimethyl sulfoxide (DMSO, brand name RIMSO-50, by Mylan Pharmaceutical), was the first and remains the only FDA-approved bladder instillation specifically for Interstitial Cystitis (IC). It was approved in 1978, and its exact mechanism of action is still not fully known, though it is believed to have several positive effects such as anti-inflammatory, antispasmodic, painkiller, and increasing bladder capacity by breaking down scar tissue by preventing the formation of collagen, a protein the body uses to create scar tissue.

The current treatment of IC also follows use of interventions as monotherapies or Combination Therapies. Monotherapy includes Oral Medications, Intravesical Instillations, and Other treatment options while combination therapy involves combination of one or more of these therapies.

Key Findings

This section includes a glimpse of the Interstitial Cystitis (IC) 7MM market.

The United States accounts for the largest market size of Interstitial Cystitis (IC), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
The market size of Interstitial Cystitis in the seven major markets was found to be USD 1,599 Million in 2017, which will increase in the the study period 2017–2030.
Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Interstitial Cystitis. Owing to the positive outcomes of the several products during the developmental stage by key players such as Kyorin Pharmaceutical, UCB Pharma, Lipella Pharmaceuticals, Grünenthal and Astellas Pharma, the market is expected to witness a significant positive shift in the Interstitial Cystitis Market Size.
Among the EU5 countries, Germany was estimated to have the highest market size with USD 90 Million in 2017, while Spain was found to have the lowest market size of Interstitial Cystitis with USD 53 Million in 2017.
In Japan, the market size was estimated to be USD 90 Million in 2017, which is anticipated to increase by 2030.

The United States Market Outlook

This section provides the total Interstitial Cystitis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Interstitial Cystitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Interstitial Cystitis market size and market size by therapies in Japan is also mentioned.

Interstitial Cystitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Interstitial Cystitis market or expected to get launched in the market during the study period 2017-2030. The analysis covers Interstitial Cystitis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Interstitial Cystitis Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Interstitial Cystitis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Interstitial Cystitis emerging therapies.

Reimbursement Scenario in Interstitial Cystitis
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Interstitial Cystitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Interstitial Cystitis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Interstitial Cystitis Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
The report covers the descriptive overview of Interstitial Cystitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Interstitial Cystitis epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Interstitial Cystitis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Interstitial Cystitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Interstitial Cystitis market

Report Highlights
In the coming years, Interstitial Cystitis (IC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Cystitis (IC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
The report contains Gender-specific prevalence of IC in the 7MM, wherein females are found to suffer more as compared to male.
Report also covers Severity-based Diagnosed Prevalent Population of Interstitial Cystitis, including several mild, moderate and severe IC.
DelveInsight has also estimated Type-specific Diagnosed Prevalent Population of Interstitial Cystitis, comprising of Non-ulcerative and Ulcerative types. It was found that the Non-ulcerative is more prevalent across the 7MM.
The report also encompasses another major segment, i.e., Age-specific Diagnosed Prevalent Population of Interstitial Cystitis, wherein various age groups have been considered, such as 18–35, 36–55, 56–74 and 75+. It has been found that IC majorly affects patients whose age is 40 years or above.
The current US market of IC is mainly dominated by the use of monotherpies and combination therapies.
DelveInsight estimates that there are several upcoming therapies targeting specific IC patient pool, such as Kyorin Pharmaceutical, UCB Pharma, Lipella Pharmaceuticals, Grünenthal and Astellas Pharma. Kyorin Pharmaceutical is developing KRP-116D, which has completed phase III trial and is expected to enter the market soon. It has shown improvements in IC/BPS symptoms, bladder pain and voiding parameters. On the other hand, Certolizumab pegol (Cimzia) by UCB Pharma has also completed phase III trial in the US and has demonstrated an acceptable safety profile for treating IC/BPS due to occurrence of microbiologically documented urinary infection in patients.
Interstitial Cystitis Report Insights
Patient Population
Therapeutic Approaches
Interstitial Cystitis Pipeline Analysis
Interstitial Cystitis Market Size and Trends
Interstitial Cystitis Market Opportunities
Impact of upcoming Interstitial Cystitis Therapies

Interstitial Cystitis Report Key Strengths
11 Years Interstitial Cystitis Forecast
7MM Coverage
Interstitial Cystitis Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Interstitial Cystitis Market
Interstitial Cystitis Drugs Uptake

Interstitial Cystitis Report Assessment
Current Treatment Practices
Interstitial Cystitis Unmet Needs
Pipeline Product Profiles
Interstitial Cystitis Market Attractiveness
Interstitial Cystitis Market Drivers and Interstitial Cystitis Market Barriers

Key Questions
Market Insights:

What was the Interstitial Cystitis market share (%) distribution in 2017 and how it would look like in 2030?
What would be the Interstitial Cystitis total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Interstitial Cystitis market size during the forecast period (2017-2030)?
At what CAGR, the Interstitial Cystitis market is expected to grow in 7MM during the forecast period (2017-2030)?
What would be the Interstitial Cystitis market outlook across the 7MM during the forecast period (2017-2030)?
What would be the Interstitial Cystitis market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Interstitial Cystitis?
What is the historical Interstitial Cystitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Interstitial Cystitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Interstitial Cystitis?
Out of all 7MM countries, which country would have the highest prevalent population of Interstitial Cystitis during the forecast period (2017-2030)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
What are the current options for the Interstitial Cystitis treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Interstitial Cystitis in the USA, Europe, and Japan?
What are the Interstitial Cystitis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Interstitial Cystitis?
How many therapies are developed by each company for Interstitial Cystitis treatment?
How many are emerging therapies in mid-stage, and late stage of development for Interstitial Cystitis treatment?
What are the key collaborations (Industry – Industry, Industry – Academia), Mergers and acquisitions, licensing activities related to the Interstitial Cystitis therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Interstitial Cystitis and their status?
What are the key designations that have been granted for the emerging therapies for Interstitial Cystitis?
What are the global historical and forecasted market of Interstitial Cystitis?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Interstitial Cystitis market
To understand the future market competition in the Interstitial Cystitis market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Interstitial Cystitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Interstitial Cystitis market
To understand the future market competition in the Interstitial Cystitis market

【レポートの目次】

1 Key Insights

2 Interstitial Cystitis Market Overview at a Glance

2.1 Market Share (%) Distribution of Interstitial Cystitis in 2017

2.2 Market Share (%) Distribution of Interstitial Cystitis in 2030

3 Interstitial Cystitis (IC): Disease Background and Overview

3.1 Introduction

3.2 Causes

3.3 Risk Factors

3.4 Signs and Symptoms

3.5 Pathophysiology

3.6 Diagnosis

3.6.1 Physical examination

3.6.2 Ultrasound/pelvic imaging

3.6.3 Frequency volume chart +/− post-void residual

3.6.4 Laboratory tests: Urinalysis, culture, cytology

3.6.5 Symptom scores

3.6.6 Cystoscopy

3.6.7 Potassium sensitivity test

3.6.8 Intravesical anesthetic bladder challenge

3.6.9 Hydrodistension

3.6.10 Urodynamics (UDS)

3.6.11 Bladder biopsy

3.7 Diagnostic Guidelines for IC/BPS by American Urology Association (AUA)

3.8 Biomarkers for patients with interstitial cystitis

4 Epidemiology and Patient Population

4.1 Key Findings

4.2 G6 Total Prevalent Population of Interstitial Cystitis

4.3 7MM Total Diagnosed Prevalent Population of Interstitial Cystitis

5 Country-Wise Epidemiology of Interstitial Cystitis Syndrome

5.1 United States

5.1.1 Assumptions and Rationale

5.1.2 Total Prevalent Population of Interstitial Cystitis in the United States

5.1.3 Gender-specific Prevalent Population of Interstitial Cystitis in the United States

5.1.4 Total Diagnosed Prevalent Population of Interstitial Cystitis in the United States

5.1.5 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in the United States

5.1.6 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States

5.1.7 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States

5.2 EU5 Countries

5.2.1 Assumptions and Rationale

5.3 Germany

5.3.1 Assumptions and Rationale

5.4 Germany

5.4.1 Total Prevalent Population of Interstitial Cystitis in Germany

5.4.2 Gender-specific Prevalent Population of Interstitial Cystitis in Germany

5.4.3 Total Diagnosed Prevalent Population of Interstitial Cystitis in Germany

5.4.4 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Germany

5.4.5 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany

5.4.6 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany

5.5 France

5.5.1 Assumptions and Rationale

5.5.2 Total Prevalent Population of Interstitial Cystitis in France

5.5.3 Gender-specific Prevalent Population of Interstitial Cystitis in France

5.5.4 Total Diagnosed Prevalent Population of Interstitial Cystitis in France

5.5.5 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in France

5.5.6 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in France

5.5.7 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in France

5.6 Italy

5.6.1 Assumptions and Rationale

5.6.2 Total Prevalent Population of Interstitial Cystitis in Italy

5.6.3 Gender-specific Prevalent Population of Interstitial Cystitis in Italy

5.6.4 Total Diagnosed Prevalent Population of Interstitial Cystitis in Italy

5.6.5 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Italy

5.6.6 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy

5.6.7 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy

5.7 Spain

5.7.1 Assumptions and Rationale

5.7.2 Total Prevalent Population of Interstitial Cystitis in Spain

5.7.3 Gender-specific Prevalent Population of Interstitial Cystitis in Spain

5.7.4 Total Diagnosed Prevalent Population of Interstitial Cystitis in Spain

5.7.5 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Spain

5.7.6 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain

5.7.7 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain

5.8 United Kingdom

5.8.1 Assumptions and Rationale

5.8.2 Total Prevalent Population of Interstitial Cystitis in the United Kingdom

5.8.3 Gender-specific Prevalent Population of Interstitial Cystitis in the United Kingdom

5.8.4 Total Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom

5.8.5 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom

5.8.6 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom

5.8.7 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom

5.9 Japan

5.9.1 Assumptions and Rationale

5.9.2 Total Diagnosed Prevalent Population of Interstitial Cystitis in Japan

5.9.3 Gender-specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan

5.9.4 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Japan

5.9.5 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan

5.9.6 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan

6 Treatment Algorithm, Current Treatment, and Medical Practices

6.1 Treatment

6.2 Treatment Algorithm

6.2.1 United States

6.2.2 Europe

6.2.3 Japan

6.3 Guideline-based Intravesical Pharmacotherapies

7 Recognized Establishments

8 Unmet Needs

9 Marketed Drugs

9.1 Elmiron: Janssen Pharmaceutical

9.1.1 Drug Description

9.1.2 Mechanism of action

9.1.3 Regulatory Milestones

9.1.4 Advantages & Disadvantages

9.1.5 Safety and Efficacy

9.1.6 Product Profile

10 Instillations

10.1 RIMSO-50: Mylan Pharmaceutical

10.1.1 Drug Description

10.1.2 Mechanism of Action

10.1.3 Regulatory Milestones

10.1.4 Advantages & Disadvantages

10.1.5 Safety and Efficacy

10.1.6 Product Profile

10.2 Cystistat: Bioniche Life Sciences Inc

10.2.1 Drug Description

10.2.2 Mechanism of Action

10.2.3 Regulatory Milestones

10.2.4 Advantages & Disadvantages

10.2.5 Safety and Efficacy

10.2.6 Product Profile

10.3 Gepan instill: Pohl-Boskamp GmbH

10.3.1 Drug Description

10.3.2 Mechanism of Action

10.3.3 Advantages & Disadvantages

10.3.4 Safety and Efficacy

10.3.5 Product Profile

10.4 Uracyst: Stellar Pharmaceuticals

10.4.1 Drug Description

10.4.2 Regulatory Milestones

10.4.3 Advantages & Disadvantages

10.4.4 Safety and Efficacy

10.4.5 Product Profile

10.5 Hyacyst: Syner-Med

10.5.1 Drug Description

10.5.2 Advantages & Disadvantages

10.5.3 Safety and Efficacy

10.5.4 Product Profile

10.6 iAluRil: Aspire Pharma

10.6.1 Drug Description

10.6.2 Mechanism of Action

10.6.3 Advantages & Disadvantages

10.6.4 Safety and Efficacy

10.6.5 Product Profile

11 Emerging Therapies

11.1 Key Cross Competition

11.2 KRP-116D: Kyorin Pharmaceutical

11.2.1 Product Description

11.2.2 Other Developmental Activities

11.2.3 Clinical Development

11.2.4 Safety and Efficacy

11.2.5 Product Profile

11.3 Certolizumab pegol (Cimzia): UCB Pharma

11.3.1 Product Description

11.3.2 Clinical Development

11.3.3 Safety and Efficacy

11.3.4 Product Profile

11.4 LP-08: Lipella Pharmaceuticals

11.4.1 Product Description

11.4.2 Other Developmental Activities

11.4.3 Clinical Development

11.4.4 Safety and Efficacy

11.4.5 Product Profile

11.5 GRT6010: Grünenthal

11.5.1 Product Description

11.5.2 Clinical Development

11.5.3 Safety and Efficacy

11.5.4 Product Profile

11.6 ASP6294: Astellas Pharma

11.6.1 Product Description

11.6.2 Clinical Development

11.6.3 Safety and Efficacy

11.6.4 Product Profile

11.7 SI-722: Seikagaku Corporation

11.7.1 Product Description

11.7.2 Other Developmental Activities

11.7.3 Clinical Development

11.7.4 Product Profile

12 Interstitial Cystitis: 7 Major Market Analysis

12.1 Key Findings

12.2 Market Size of Interstitial Cystitis in the 7MM

13 The United States Market Outlook

13.1 United States Market Size

13.1.1 Total Market size of Interstitial Cystitis

13.1.2 Market Size by Therapies

14 EU-5 Countries: Market Outlook

14.1 Germany

14.1.1 Total Market size of Interstitial Cystitis in Germany

14.1.2 Market Size by Therapies

14.2 France

14.2.1 Total Market Size of Interstitial Cystitis

14.2.2 Market Size by Therapies

14.3 Italy

14.3.1 Total Market Size of Interstitial Cystitis

14.3.2 Market Size by Therapies

14.4 Spain

14.4.1 Total Market Size of Interstitial Cystitis

14.4.2 Market Size by Therapies

14.5 United Kingdom

14.5.1 Total Market Size of Interstitial Cystitis

14.5.2 Market Size by Therapies

15 Japan: Market Outlook

15.1 Japan market Size

15.1.1 Total Market Size of Interstitial Cystitis

15.1.2 Market Size by Therapies

16 KOL Reviews

17 Case Reports

17.1 Painful Bladder Syndrome/Interstitial Cystitis Successful Treatment with Montelukast: A Case Report and Literature Review (United States)

17.2 The Burden of Bladder Pain in Five European Countries: A Cross-sectional Study

17.3 A survey on the clinical practice of interstitial cystitis in Japan

18 Market Drivers

19 Market Barriers

20 SWOT Analysis

21 Appendix

21.1 Bibliography

21.2 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

Table 1 : 7MM Interstitial Cystitis Epidemiology (2017-2030)

Table 2 : 7MM Interstitial Cystitis Diagnosed and Treatable Cases (2017-2030)

Table 3 : Disease% Epidemiology in the United States (2017-2030)

Table 4 : Interstitial Cystitis Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 : Interstitial Cystitis Epidemiology in Germany (2017-2030)

Table 6 : Interstitial Cystitis Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 : Interstitial Cystitis Epidemiology in France (2017-2030)

Table 8 : Interstitial Cystitis Diagnosed and Treatable Cases in France (2017-2030)

Table 9 : Interstitial Cystitis Epidemiology in Italy (2017-2030)

Table 10 : Interstitial Cystitis Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 : Interstitial Cystitis Epidemiology in Spain (2017-2030)

Table 12 : Interstitial Cystitis Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 : Interstitial Cystitis Epidemiology in the UK (2017-2030)

Table 14 : Interstitial Cystitis Diagnosed and Treatable Cases in the UK (2017-2030)

Table 15 : Interstitial Cystitis Epidemiology in Japan (2017-2030)

Table 16 : Interstitial Cystitis Diagnosed and Treatable Cases in Japan (2017-2030)

Table 17 : Drug Name, Clinical Trials by Recruitment status

Table 18 : Drug Name, Clinical Trials by Zone

Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Table 20 : Region-wise Market Size in USD, Million (2017-2030)

Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Table 22 : United States Market Size in USD, Million (2017-2030)

Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Table 24 : Germany Market Size in USD, Million (2017-2030)

Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Table 26 : France Market Size in USD, Million (2017-2030)

Table 27 : France Market Size by Therapy in USD, Million (2017-2030)

Table 28 : Italy Market Size in USD, Million (2017-2030)

Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Table 30 : Spain Market Size in USD, Million (2017-2030)

Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Table 32 : United Kingdom Market Size in USD, Million (2017-2030)

Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Table 34 : Japan Market Size in USD, Million (2017-2030)

Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of tables is not exhaustive; the final content may vary

Figure 1 : 7MM Interstitial Cystitis Epidemiology (2017-2030)

Figure 2 : 7MM Interstitial Cystitis Diagnosed and Treatable Cases (2017-2030)

Figure 3 : Interstitial Cystitis Epidemiology in the United States (2017-2030)

Figure 4 : Interstitial Cystitis Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 : Interstitial Cystitis Epidemiology in Germany (2017-2030)

Figure 6 : Interstitial Cystitis Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 : Interstitial Cystitis Epidemiology in France (2017-2030)

Figure 8 : Interstitial Cystitis Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 : Interstitial Cystitis Epidemiology in Italy (2017-2030)

Figure 10 : Interstitial Cystitis Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 : Interstitial Cystitis Epidemiology in Spain (2017-2030)

Figure 12 : Interstitial Cystitis Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 : Interstitial Cystitis Epidemiology in the UK (2017-2030)

Figure 14 : Interstitial Cystitis Diagnosed and Treatable Cases in the UK (2017-2030)

Figure 15 : Interstitial Cystitis Epidemiology in Japan (2017-2030)

Figure 16 : Interstitial Cystitis Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 17 : Drug Name, Clinical Trials by Recruitment status

Figure 18 : Drug Name, Clinical Trials by Zone

Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Figure 20 : Region-wise Market Size in USD, Million (2017-2030)

Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Figure 22 : United States Market Size in USD, Million (2017-2030)

Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Figure 24 : Germany Market Size in USD, Million (2017-2030)

Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Figure 26 : France Market Size in USD, Million (2017-2030)

Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)

Figure 28 : Italy Market Size in USD, Million (2017-2030)

Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Figure 30 : Spain Market Size in USD, Million (2017-2030)

Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)

Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Figure 34 : Japan Market Size in USD, Million (2017-2030)

Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of figures is not exhaustive; the final content may vary.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[間質性膀胱炎治療薬の世界市場:インサイト・疫学・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆